Last $1.26 USD
Change Today 0.00 / 0.00%
Volume 563.3K
NAVB On Other Exchanges
Symbol
Exchange
NAVB is not on other exchanges.
As of 8:04 PM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

navidea biopharmaceuticals i (NAVB) Snapshot

Open
$1.28
Previous Close
$1.26
Day High
$1.33
Day Low
$1.25
52 Week High
09/23/13 - $2.89
52 Week Low
11/7/13 - $1.11
Market Cap
189.8M
Average Volume 10 Days
650.3K
EPS TTM
$-0.33
Shares Outstanding
150.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NAVIDEA BIOPHARMACEUTICALS I (NAVB)

navidea biopharmaceuticals i (NAVB) Related Businessweek News

View More BusinessWeek News

navidea biopharmaceuticals i (NAVB) Details

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company’s radiopharmaceutical development programs include Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in lymphatic mapping procedures, which are performed to evaluate breast cancer and melanoma; Manocept platform to target the CD206 mannose receptor expressed on macrophages; and NAV4694, an Fluorine-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of cognitive impairment, such as Alzheimer’s disease. Its radiopharmaceutical development programs also comprise NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson’s disease and other movement disorders with potential use as a diagnostic aid in dementia; and NAV1800, a radiolabeled monoclonal antibody that is developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, primarily colorectal cancer. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, AstraZeneca AB, Alseres Pharmaceuticals, Inc., and The Ohio State University. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

57 Employees
Last Reported Date: 03/14/14
Founded in 1983

navidea biopharmaceuticals i (NAVB) Top Compensated Officers

President and Chief Business Officer
Total Annual Compensation: $334.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $274.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $300.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $276.4K
Compensation as of Fiscal Year 2013.

navidea biopharmaceuticals i (NAVB) Key Developments

Navidea Biopharmaceuticals, Inc. Receives Orphan Drug Designation from FDA for Use of Lymphoseek in Head and Neck Cancers

Navidea Biopharmaceuticals Inc. announced that Lymphoseek Injection has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for use in sentinel lymph node detection in patients with cancer of the head and neck. The designation is based upon an estimated 40,000 procedures being performed in this patient population. The FDA Office of Orphan Products Development mission is to advance the evaluation and development of products hat demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

Navidea Biopharmaceuticals, Inc Signs Contract with Subsidiary of Hainan Sinotau Pharmaceutical

Navidea Biopharmaceuticals Inc. has signed a contract with a subsidiary of Hainan Sinotau Pharmaceutical. The contract has been signed to develop and commercialize Lymphoseek (technetium Tc 99m tilmanocept) Injection in China. The product is a new receptor-targeted, small-molecule radiopharmaceutical approved in the US for use in lymphatic mapping to assist in the detection of lymph nodes in patients with breast cancer or melanoma. It is also indicated for use in guiding sentinel lymph node biopsy in certain oral cancer patients. Under the contract, Navidea will earn royalties on units sales, an upfront payment of USD 300,000, up to USD 700,000 in development milestone payments, and up to USD 1.5 million in sales-related milestones.

Navidea Biopharmaceuticals, Inc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Navidea Biopharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $1,074,690 compared to $195,277 a year ago. Loss from operations was $9,215,558 compared to $8,456,431 a year ago. Net loss attributable to common stockholders was $10,222,234 or $0.07 per basic and diluted share compared to $10,300,351 or $0.09 per basic and diluted share a year ago. For six months, the company reported revenue of $1,826,494 compared to $195,277 a year ago. Loss from operations was $17,794,601 compared to $15,460,678 a year ago. Net loss attributable to common stockholders was $21,962,787 or $0.15 per basic and diluted share compared to $17,641,370 or $0.15 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NAVB:US $1.26 USD 0.00

NAVB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $13.42 USD -0.28
CTI BioPharma Corp $2.50 USD -0.01
Curis Inc $1.47 USD +0.03
Exact Sciences Corp $19.00 USD +0.15
Infinity Pharmaceuticals Inc $13.54 USD -0.20
View Industry Companies
 

Industry Analysis

NAVB

Industry Average

Valuation NAVB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 68.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 51.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NAVIDEA BIOPHARMACEUTICALS I, please visit www.navidea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.